ONCOLYTICS BIOTECH
Oncolytics Biotech focuses the research and development efforts on the development of REOLYSIN, the cancer therapeutic. The product for human use, REOLYSIN is developed from the reovirus. The virus has been demonstrated to replicate in the tumour cells bearing an activated Ras pathway. The Ras protein is a regulator of cell growth and differentiation. It transmits signals from the cell's surface, through growth factor receptors, to downstream elements, which are in turn relayed to the nucleus. T... he transmission of signals from the cell surface to the cell's nucleus is referred to as the signal transduction. The wholly owned subsidiaries of the company include Oncolytics Biotech (Barbados) Inc. and Oncoltics Biotech (US) Inc. In April 2009, the Company completed the acquisition of an inactive private company. Oncolytics Biotech was founded on 1988 and is based in Calgary, Alberta, Canada.
ONCOLYTICS BIOTECH
Industry:
Biotechnology Health Care Medical Therapeutics Wellness
Founded:
1988-01-01
Address:
Calgary, Alberta, Canada
Country:
Canada
Website Url:
http://www.oncolyticsbiotech.com
Total Employee:
11+
Status:
Active
Contact:
403.670.7377
Email Addresses:
[email protected]
Total Funding:
80.1 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager Content Delivery Network
Similar Organizations
Adamas Pharmaceuticals
Adamas Pharmaceuticals develops controlled release combination therapeutics for infectious diseases and central nervous system disorders.
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Semma Therapeutics
Semma Therapeutics was founded to develop transformative therapies for Type 1 diabetes patients.
Garden of Alice
Garden of Alice offers a strategic direction in delivering products and therapeutics that help in nourishing the body and soul.
Current Employees Featured
Founder
Stock Details
Key Employee Changes
| Date | New article |
|---|---|
| 2021-12-21 | Oncolytics Biotech® Promotes Thomas C. Heineman, M.D., Ph.D., to Chief Medical Officer |
Official Site Inspections
http://www.oncolyticsbiotech.com Semrush global rank: 4.23 M Semrush visits lastest month: 2.77 K
- Host name: oncolytics.tempurl.host
- IP address: 149.28.195.92
- Location: San Jose United States
- Latitude: 37.3387
- Longitude: -121.8914
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 95113
More informations about "Oncolytics Biotech"
Oncolytics Biotech - Wikipedia
Oncolytics Biotech Inc. is a Canadian company headquartered in Calgary, Alberta, that is developing an intravenously delivered immuno-oncolytic virus called pelareorep for the treatment of solid tumors and hematological malignancies. Pelareorep is a non-pathogenic, proprietary isolate of the unmodified reovirus that: induces selective tumor lysis and promotes an inflamed tumor phenotype through innate and adaptive immune responses. See details»
Oncolytics Biotech Inc. | LinkedIn
Oncolytics Biotech Inc. is developing pelareorep, a safe and well-tolerated intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and …See details»
Oncolytics Biotech (TSX:ONC) Company Profile & Description
Apr 25, 2025 Company profile for Oncolytics Biotech Inc. (TSX:ONC) with a description, list of executives, contact details and other key facts.See details»
Oncolytics Biotech - Crunchbase Company Profile
Oncolytics Biotech develops oncolytic viruses as potential therapeutics for use in a broad range of cancers.See details»
Oncolytics Biotech - Overview, News & Similar companies
Mar 7, 2024 View Oncolytics Biotech (www.oncolyticsbiotech.com) location in Alberta, Canada , revenue, industry and description. Find related and similar companies as well as employees …See details»
Oncolytics Biotech Company Profile - Office Locations ... - Craft
Oct 29, 2024 Oncolytics Biotech has 5 employees across 3 locations. See insights on Oncolytics Biotech including office locations, competitors, revenue, financials, executives, subsidiaries …See details»
Oncolytics Biotech 2025 Company Profile: Stock …
Information on stock, financials, earnings, subsidiaries, investors, and executives for Oncolytics Biotech. Use the PitchBook Platform to explore the full profile.See details»
Committed to helping patients with cancer | Oncolytics …
At Oncolytics, we are committed to giving patients with cancer the opportunity to live longer, better lives. Our mission is to offer patients more of what they need: More quality time with family, more time for their passions, and more of what …See details»
Oncolytics Biotech Inc Company Profile - Overview - GlobalData
Oncolytics Biotech Inc (Oncolytics) is a biopharmaceutical company. It is developing pelareorep, an intravenous immunotherapeutic agent derived from a non-pathogenic reovirus. This …See details»
Oncolytics Biotech Inc Company Profile | Calgary, AB, Canada ...
Find company research, competitor information, contact details & financial data for Oncolytics Biotech Inc of Calgary, AB. Get the latest business insights from Dun & Bradstreet.See details»
Oncolytics Biotech (Canada) Funding: $100.1M
Jul 7, 2025 Oncolytics Biotech is developing REOLYSIN®, a safe and well-tolerated intravenously delivered immuno-oncolytic virus (IOV) that targets cancer through a unique …See details»
Oncolytics Biotech - 2025 Company Profile - Tracxn
Jul 12, 2025 Oncolytics Biotech is a public company based in Calgary (Canada), founded in 1998. It operates as a Develops oncolytic viruses for use as cancer therapeutics. Oncolytics …See details»
Investor Overview for Oncolytics Biotech | Oncolytics Biotech
3 days ago Investor Overview for Oncolytics Biotech is focused on obtaining regulatory approval for pelareorep for metastatic breast cancer and pancreatic cancer.See details»
Oncolytics Biotech Inc. Overview | SignalHire Company Profile
Oncolytics Biotech Inc. is a public company that has been in the industry for 25 years. The company currently specializes in the Biotechnology area. The position of the President & CEO …See details»
Oncolytics Biotech® to Present New Clinical Trial Data at
May 23, 2025 For more about Oncolytics, please visit: www.oncolyticsbiotech.com or follow the company on social media on LinkedIn and on X @ oncolytics.See details»
Oncolytics Biotech Corporate Governance | Oncolytics Biotech
Oncolytics Biotech Corporate Governance documents, important links, Board Members, Board Committees and Board Diversity MatrixSee details»
Oncolytics Biotech® to Engage FDA for Potential Registration …
3 days ago For more about Oncolytics, please visit: www.oncolyticsbiotech.com or follow the Company on social media on LinkedIn and on X @ oncolytics. Forward-looking statementsSee details»
Oncolytics Biotech® to Engage FDA for Potential Registration …
3 days ago Oncolytics Biotech® Inc. (Nasdaq: ONCY) (TSX: ONC) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today …See details»
Press Releases for Oncolytics Biotech | Oncolytics Biotech
Jul 23, 2025 News releases for Oncolytics Biotech, sorted by year and clinical trialsSee details»
Oncolytics Biotech® to Engage FDA for Potential Registration …
3 days ago Oncolytics is actively pursuing strategic partnerships to accelerate development and maximize commercial impact. For more about Oncolytics, please visit: …See details»